Phoenix Cardiac has closed an equity financing round at nearly $5 million. The startup intends to use the money to help it gain CE mark approval for its BACE device, which is designed for treating functional mitral valve regurgitation, and aims to launch the product by partnering with a larger company.
Cardiac device startup gets boost of almost $5M
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.